A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes BOOST: INTENSIFY PREMIX/ALL 2
Phase of Trial: Phase III
Latest Information Update: 26 Jun 2018
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BOOST
- Sponsors Novo Nordisk
- 26 Jun 2018 Primary endpoint (Change from baseline in HbA1c (%) (glycosylated haemoglobin)) has been met, according to results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2018 Results (n=541) presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.